|
1
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Ribeiro U Jr, Posner MC, Safatle-Ribeiro
AV and Reynolds JC: Risk factors for squamous cell carcinoma of the
oesophagus. Br J Surg. 83:1174–1185. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu JC, Tao H, Zhang YQ, Zha WW, Qian PD,
Li F and Xu KX: Extent of prophylactic postoperative radiotherapy
after radical surgery of thoracic esophageal squamous cell
carcinoma. Dis Esophagus. 21:502–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ismail NI, Kaur G, Hashim H and Hassan MS:
S100A4 overexpression proves to be independent marker for breast
cancer progression. Cancer Cell Int. 8:122008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang H, Quah SY, Dong JM, Manser E, Tang
JP and Zeng Q: PRL-3 down-regulates PTEN expression and signals
through PI3K to promote epithelial-mesenchymal transition. Cancer
Res. 67:2922–2926. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Birchmeier C, Birchmeier W and
Brand-Saberi B: Epithelial-mesenchymal transitions in cancer
progression. Acta Anat (Basel). 156:217–226. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hay ED: An overview of
epithelio-mesenchymal transformation. Acta Anat (Basel). 154:8–20.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu J, Lamouille S and Derynck R:
TGF-β-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009.
|
|
12
|
Boyer B, Valles AM and Edme N: Induction
and regulation of epithelial-mesenchymal transitions. Biochem
Pharmacol. 60:1091–1099. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: new insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moustakas A and Heldin CH: Signaling
networks guiding epithelial-mesenchymal transitions during
embryogenesis and cancer progression. Cancer Sci. 98:1512–1520.
2007. View Article : Google Scholar
|
|
15
|
Zavadil J and Bottinger EP: TGF-β and
epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774.
2005.
|
|
16
|
Quan J, Elhousiny M, Johnson NW and Gao J:
Transforming growth factor-β1 treatment of oral cancer induces
epithelial-mesenchymal transition and promotes bone invasion via
enhanced activity of osteoclasts. Clin Exp Metastasis. 30:659–670.
2013.
|
|
17
|
Reichl P, Haider C, Grubinger M and
Mikulits W: TGF-β in epithelial to mesenchymal transition and
metastasis of liver carcinoma. Curr Pharm Des. 18:4135–4147.
2012.
|
|
18
|
Ellenrieder V, Hendler SF, Boeck W,
Seufferlein T, Menke A, Ruhland C, Adler G and Gress TM:
Transforming growth factor β1 treatment leads to an
epithelial-mesenchymal transdifferentiation of pancreatic cancer
cells requiring extracellular signal-regulated kinase 2 activation.
Cancer Res. 61:4222–4228. 2001.
|
|
19
|
Zhang S and Yu D: PI(3)king apart PTEN’s
role in cancer. Clin Cancer Res. 16:4325–4330. 2010.PubMed/NCBI
|
|
20
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wallin JJ, Guan J, Edgar KA, Zhou W,
Francis R, Torres AC, Haverty PM, Eastham-Anderson J, Arena S,
Bardelli A, et al: Active PI3K pathway causes an invasive phenotype
which can be reversed or promoted by blocking the pathway at
divergent nodes. PLoS One. 7:e364022012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Karamitopoulou E: Tumor budding cells,
cancer stem cells and epithelial-mesenchymal transition-type cells
in pancreatic cancer. Front Oncol. 2:2092013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang HY, Zheng XZ, Wang XH, Xuan XY, Wang
F and Li SS: S100A4 mediated cell invasion and metastasis of
esophageal squamous cell carcinoma via the regulation of MMP-2 and
E-cadherin activity. Mol Biol Rep. 39:199–208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wendt MK, Allington TM and Schiemann WP:
Mechanisms of the epithelial-mesenchymal transition by TGF-β.
Future Oncol. 5:1145–1168. 2009.
|
|
25
|
Sun Y, Li SS, Wang XH, Wang XJ and Yan AH:
Transforming growth factor beta1 regulation of
epithelial-mesenchymal transition in esophagus squamous cell
carcinoma. Zhonghua Bing Li Xue Za Zhi. 37:542–548. 2008.(In
Chinese).
|
|
26
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leslie NR, Yang X, Downes CP and Weijer
CJ: PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in
the control of cell migration. Curr Biol. 17:115–125. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Inoue K, Fry EA and Taneja P: Recent
progress in mouse models for tumor suppressor genes and its
implications in human cancer. Clin Med Insights Oncol. 7:103–122.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Simpson L and Parsons R: PTEN: life as a
tumor suppressor. Exp Cell Res. 264:29–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: the PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Y, Gao L, Luo X, Wang L, Gao X, Wang W,
Sun J, Dou L, Li J, Xu C, et al: Epigenetic silencing of
microRNA-193a contributes to leukemogenesis in t(8;21) acute
myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood.
121:499–509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mulholland DJ, Kobayashi N, Ruscetti M,
Zhi A, Tran LM, Huang J, Gleave M and Wu H: Pten loss and RAS/MAPK
activation cooperate to promote EMT and metastasis initiated from
prostate cancer stem/progenitor cells. Cancer Res. 72:1878–1889.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bian Y, Hall B, Sun ZJ, Molinolo A, Chen
W, Gutkind JS, Waes CV and Kulkarni AB: Loss of TGF-β signaling and
PTEN promotes head and neck squamous cell carcinoma through
cellular senescence evasion and cancer-related inflammation.
Oncogene. 31:3322–3332. 2012.
|
|
34
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005.
|
|
35
|
Chen KC, Chen CY, Lin CJ, Yang TY, Chen
TH, Wu LC and Wu CC: Luteolin attenuates TGF-β1-induced
epithelial-mesenchymal transition of lung cancer cells by
interfering in the PI3K/Akt-NF-κB-Snail pathway. Life Sci.
93:924–933. 2013.PubMed/NCBI
|
|
36
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: implications in
development and cancer. Development. 132:3151–3161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cano A, Perez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moustakas A and Heldin CH: Induction of
epithelial-mesenchymal transition by transforming growth factor β.
Semin Cancer Biol. 22:446–454. 2012.
|
|
39
|
Lv ZD, Kong B, Li JG, Qu HL, Wang XG, Cao
WH, Liu XY, Wang Y, Yang ZC, Xu HM and Wang HB: Transforming growth
factor-β 1 enhances the invasiveness of breast cancer cells by
inducing a Smad2-dependent epithelial-to-mesenchymal transition.
Oncol Rep. 29:219–225. 2013.
|
|
40
|
Ju X, Casimiro MC, Gormley M, Meng H, Jiao
X, Katiyar S, Crosariol M, Chen K, Wang M, Quong AA, et al:
Identification of a cyclin D1 network in prostate cancer that
antagonizes epithelial-mesenchymal restraint. Cancer Res.
74:508–519. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bakin AV, Tomlinson AK, Bhowmick NA, Moses
HL and Arteaga CL: Phosphatidylinositol 3-kinase function is
required for transforming growth factor β-mediated epithelial to
mesenchymal transition and cell migration. J Biol Chem.
275:36803–36810. 2000.
|
|
42
|
Li DM and Sun H: TEP1, encoded by a
candidate tumor suppressor locus, is a novel protein tyrosine
phosphatase regulated by transforming growth factor β. Cancer Res.
57:2124–2129. 1997.PubMed/NCBI
|
|
43
|
Blobe GC, Schiemann WP and Lodish HF: Role
of transforming growth factor β in human disease. N Engl J Med.
342:1350–1358. 2000.
|
|
44
|
Krymskaya VP, Hoffman R, Eszterhas A,
Ciocca V and Panettieri RA Jr: TGF-β 1 modulates EGF-stimulated
phosphatidylinositol 3-kinase activity in human airway smooth
muscle cells. Am J Physiol. 273:L1220–L1227. 1997.
|
